

Brown's Q3, Level 2, Unit 1, Quad Central, Triq L-Esportaturi, Central Business District,
CBD1020, Malta

9th May 2025

COMPANY ANNOUNCEMENT

The following is a Company Announcement issued by Brown's Pharma Holdings p.l.c. (the **'Company'**) pursuant to the Capital Markets Rules issued by the Malta Financial Services Authority.

Quote

Variance from 2024 Financial Projections

The Company makes reference to Company Announcement Ref. No. BRW30 wherein the Company announced the approval of the Company's annual report and audited financial statements for the year ended 31st December 2024.

As transpires from the consolidated financial statements of the Company, the Brown's Pharma Group (the **'Group'**) registered revenues in the amount of €50,059,224 and a profit after tax of €2,208,053 (2023 – €38,343,467 and €1,570,716, respectively) resulting in an increase in profitability of 40.6% compared to 2023. Such growth resulted from the Group's continued development of its retail network, the acquisition of three new pharmacy licenses, and an increase in revenue for Mediva Pharma Limited. The increase in revenue and profitability of the Group is a testament to the Group's commitment towards its existing and expanding retail operations and customer base.

When compared to the forecasts contained in the Financial Analysis Summary dated 24th June 2024, the profit after tax for 2024 varies to that projected by 28%. This variance is mainly attributable to an increase in market-driven salaries and wages due to the increase in staff complement, and increase in cost of sales.

Unquote



Dr Jean C. Farrugia
Company Secretary